Latent hepatitis B diagnostic approach improvement in blood donors

Abstract

Aim. The improvement of the target algorithm for diagnosing latent hepatitis B based on the results of a screening examination of blood donors.

Material and methods. The analysis of regulatory documents was carried out. The cards of donors taken away from the donation were analyzed selectively (n=840). Research the change line of the hepatitis B incidence in the Republic of Tatarstan population for 2010–2020.

Results. Despite the decrease in the incidence of viral hepatitis B among the Republic of Tatarstan population, the detection rate of anti-HBcor in the donor group is 38 cases per 1000 donors in 2010 and 4 cases in 2020, including 4 cases with anti-HBcorIgM and 1 case per 1000 donors respectively.

Conclusion. The introduction of the latent hepatitis B diagnosis and dispensary monitoring of donors with suspected latent infection into clinical practice requires close cooperation between an infectious disease specialist, a transfusiologist and a hospital epidemiologist to prescribe an extended diagnostic examination and identify therapy (including antiviral) with a mandatory epidemiological investigation of the focus hepatitis in each case diverted from blood donation.

Keywords:diagnostics; hepatitis B; donors

Funding. The study was not sponsored.

Conflict of interest. The authors declare that there is no conflict of interest.

Contribution. Concept and design of the study – Fazylov V.Kh., Eremeeva Zh.G., Turaev R.G.; collection and processing of the material – Fazylov V.Kh., Eremeeva Zh.G., Turaev R.G.; statistical processing – Fazylov V.Kh., Eremeeva Zh.G., Turaev R.G.; editing by Fazylov V.Kh.

For citation: Fazylov V.Kh., Eremeeva Zh.G., Turaev R.G. Latent hepatitis B diagnostic approach improvement in blood donors. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2023; 12 (1): 54–61. DOI: https://doi.org/10.33029/2305-3496-2023-12-1-54-61 (in Russian)

References

1. Altindis M., Uslan I., Cetinkaya Z. [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B]. Mikrobiyol Bul. 2007; 41 (2): 227–33.

2. French A.L., Operskalski E., Peters M. Isolated hepatitis ?В core antibody is associated with HIV and ongoing but not resolved hepatitis ?С virus infection in a cohort of US women. J Infect Dis. 2007; 195 (10): 1437–42.

3.Lampertico P., Agarwal K., Berg T.; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2017; 67 (2): 370–98.

4. Prevention of infectious diseases. Epidemiological surveillance of hepatitis B: Guidelines. Moscow: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, 2010: 37 p. (in Russian)

5. Kamyshnikov V.S. Handbook of clinical and biochemical studies and laboratory diagnostics. Moscow: MEDPress-inform; 2004: 920 p. (in Russian)

6.On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2020: State report. Kazan’: Upravlenie Federal’noy sluzhby po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka po Respublike Tatarstan (Tatarstan), 2021: 366 p.

7. Hu L.P., Liu D.P., Chen Q.Y. Occult HBV infection may be transmitted through close contact and manifest as an overt infection. PLoS One. 2015; 10 (10). DOI: https://doi.org/10.1371/journal.pone.0138552

8. Nikogosova A.D., Umrik D.V., Tsirul’nikova O.M. De novo HBV infection in patients after liver transplantation. Vestnik transplantologii i iskusstvennykh organov [Bulletin of Transplantology and Artificial Organs]. 2022; 24 (3): 37–41. DOI: https://doi.org/10.15825/1995-1191-2022-3-37-41 (in Russian)

9. Zakharchenko G.L., Zamulina L.N. General epidemiological patterns of viral hepatitis B and C in the Orel Region. Infektsiya i immunitet [Infection and Immunity]. 2012; 2 (1–2): 442. (in Russian)

10. Federal Law of July 20, 2012 No. 125 FZ (as amended on March 7, 2018) «On the donation of blood and its components» (as amended and supplemented, effective from January 1, 2019). URL: http://www.consultant.ru/document/cons_doc_LAW_132904/ (date of access November 17, 2021). (in Russian)

11.Order of the Ministry of Health of the Russian Federation dated October 28, 2020 No. 1166n «On approval of the procedure for donors to undergo a medical examination and a list of medical contraindications (temporary and permanent) for donating blood and (or) its components and the timing of the withdrawal to which a person is subject in the presence of temporary medical indications, from donation of blood and (or) its components». URL: https://www.garant.ru/products/ipo/prime/doc/74861670 (date of access December 01, 2021). (in Russian)

12.Decree of the Government of the Russian Federation of June 22, 2019 No. 797 «On approval of the Rules for the procurement, storage, transportation and clinical use of donor blood and its components and on the invalidation of certain acts of the Government of the Russian Federation». URL: https://base.garant.ru/72284110/ (date of access December 01, 2021). (in Russian)

13. SanPiN 3.3686-21 «Sanitary and epidemiological requirements for the prevention of infectious diseases». https://docs.cntd.ru/document/573660140 (date of access November 18, 2021). (in Russian)

14. Torbenson M., Thomas D.L. Occult hepatitis B. Lancet Infect Dis. 2002; 2: 479–86.

15. Raimondo J.P., Allain, M.R. Brunetto Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008; 49: 652–7.

16. Raimondo J., Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet. 2005; 365: 638–40.

17. Abdurakhmanov D.T. Chronic hepatitis B and D: issues of pathogenesis, diagnosis and treatment. Lechebnoe delo [Medical Care]. 2004; (3): 22–33. (in Russian)

18. Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother. 2005; 55 (5): 608.

19. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005; 42: 302–30.

20. Torbenson M., Thomas D.L. Occult hepatitis B. Lancet Infect Dis. 2002; 2: 479–86.

21. Decree of the Ministry of Health of the Republic of Tatarstan dated January 30, 2017 No. 3 «On strengthening measures to prevent post-transfusion hepatitis in the territory of the Republic of Tatarstan». URL: http://16.rospotrebnadzor.ru/654 (date of access November 16, 2021). (in Russian)

22.Decree of the Government of the Russian Federation of July 4, 2020 No. 986 “On the abolition of certain acts of federal executive bodies, the recognition of certain acts and other documents of the Ministry of Health of the Russian Soviet Federative Socialist Republic as invalid on the territory of the Russian Federation and the recognition of individual acts and other documents of the Ministry of Health as invalid on the territory of the Russian Federation health care of the USSR, containing mandatory requirements, compliance with which is assessed in the implementation of state control over ensuring the safety of donor blood and its components”. URL: https://www.garant.ru/products/ipo/prime/doc/74248818/ (date of access December 01, 2021). (in Russian)

23. Mukhin M.A. Handbook of hepatology. Moscow: Litterra. 2009: 399 p. (in Russian)

24. Kaplan M.M., Keffe E.B. What do abnormal liver function test results really meaning. In: Patient Care for the Nurse Practitioner. 2003: 35–43.

25. Belyakova V.V., Dashkova N.G., Mayorova O.A., Ragimov A.A. More about ALT. Vestnik sluzhby krovi Rossii [Bulletin of the Russian Blood Service]. 2013; (2): 50–4. (in Russian)

26. Filina N.G., Kolotvina T.B., Titova S.A., Zhiburt E.B. Diagnostic significance of determining the activity of alanine aminotransferase in donor blood. Transfuziologiya [Transfusiology]. 2011; 12 (1): 9–12. (in Russian)

27. Pavlova A.V., Rabota V.YA. Significance of elevated ALT levels in the early diagnosis of viral hepatitis B, C in donors. Zdravookhranenie Dal’nego Vostoka [Health Care of the Far East]. 2016; (1): 121–2. (in Russian)

28. Kodenev A.T., Gubanova M.N., Zhiburt E.B. Screening for markers of infection in blood donors. Vestnik sluzhby krovi Rossii [Bulletin of the Russian Blood Service]. 2010; (2): 13–6. (in Russian)

29. Askari S., Schaust J. P., Deisting L.A. Donor reinstatement after elevated ALT: Is it worthwhile? Experience of a blood center. Transfusion. 2003; 43: 10.

30. Zhiburt E.B., Abzhueva O.V., Atakishiev M.M. Significance of alanine aminotransferase activity as a surrogate marker of bloodborne infections. Vestnik sluzhby krovi Rossii [Bulletin of the Russian Blood Service]. 2005; (2): 22–7. (in Russian)

31. Karpova M.V., Zaytseva G.A., Tarasova L.N., Isaeva N.V. Evaluation of some laboratory parameters in donors with elevated ALT activity. Transfuziologiya [Transfusiology]. 2007; 8 (1–2): 21. (in Russian)

32. Drepina A.S., Belyakova V.V., Appalup M.V., Mayorova O.A. Detection of viral hepatitis in the contingent of donors. Dokazatel’naya gastroenterologiya [Evidence-Based Gastroenterology]. 2016; 5 (3): 10–7. (in Russian)

33. Tankaeva Kh.S., Ilueva A.K., Zhiburt E.B. Hemotransmissible infections in blood donors and patients in the Republic of Dagestan. Transfuziologiya [Transfusiology]. 2020; 21 (1): 50–6. (in Russian)

34. Kamyshnikov V.S. Handbook of clinical and biochemical laboratory diagnostics. Minsk, 2002; (1): 389–95. (in Russian)

35. Dashkova N.G., Ragimov A.A. Diagnostic value of alanine aminotransferesis activity in blood donors. Vestnik sluzhby krovi Rossii [Bulletin of the Russian Blood Service]. 2006; (1): 19–24. (in Russian)

36. Fadeeva T.V., Ishchenkova I.V. The frequency of detection of markers of bloodborne infections in donors of the Rostov region. Vestnik sluzhby krovi Rossii [Bulletin of the Russian Blood Service]. 2006; (4): 34–6. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»